



**AMERICAN BRAIN FOUNDATION**  
 Research Advisory Committee Meeting  
 July 24, 2020  
 3:00 p.m. ET/ 2:00 p.m. CT/ 1:00 p.m. MT/ 12:00 p.m. PT  
 Conference Call

Zoom link: <https://aan.zoom.us/j/3757402880>

Committee Members	Robert Griggs, MD, Chair; Raymond Roos, MD, Vice Chair; Carsten Bonnemann, MD; Jose E. Cavazos, MD, PhD; Merit Cudkowicz, MD; James Grotta, MD; Mark Mehler, MD; John Morris, MD; Ralph Sacco, MD; Eugene Scharf, MD; Ira Shoulson, MD; Phyllis C. Zee, MD; David Dodick, MD; Natalia Rost, MD; Christy Phelps; Mary Post, MBA, CAE
Staff	Jane Ransom, ED; Julia Miglets-Nelson, PhD

AGENDA ITEM	PRESENTED BY
<b>1. Call to Order</b> <b>Approval of the May 15, 2020 minutes</b>	Robert Griggs, MD
<b>2. Update on Industry Fundraising</b>	Jane Ransom; Julia Miglets-Nelson
<b>3. Addressing Neurological Healthcare Disparities</b>	Robert Griggs, MD
<b>4. 2021 ABF Scientific Breakthrough Award</b>	Jane Ransom
<b>Adjourn</b>	

**Meeting Materials:**

- Minutes of May 15, 2020 (p. 2)
- Industry Fundraising LOI (p. 4)
- LBD Fund LOI (p. 7)
- COVID-19 and the Brain Fund LOI (p. 11)

**American Brain Foundation  
Research Advisory Committee Meeting  
May 15, 2020  
3:00 p.m. ET / 2:00 p.m. CT / 1:00 p.m. MT / 12:00 p.m. PT  
Conference Call**

**Meeting Minutes**

**In Attendance:** Robert Griggs, MD, Chair; Raymond Roos, MD, Vice Chair; Carsten Bonnemann, MD; Jose E. Cavazos, MD; Merit Cudkowicz, MD; James Grotta, MD; Mark Mehler, MD; Ralph Sacco, MD; Ira Shoulson, MD; MD; Phyllis C. Zee, MD, PhD; David Dodick, MD; Mary Post, MBA, CAE

**Staff:** Jane Ransom; Julia Miglets-Nelson, PhD

**Excused:** John Morris, MD; Eugene Scharf, MD

The meeting was called to order by Dr. Robert Griggs at 2:08 p.m. CT. The meeting minutes of March 27, 2020 were approved unanimously.

- 1. 2022 CRTF Fundraising:** Dr. Robert Griggs outlined the two major challenges facing the ABF's fundraising for the Next Generation Research Grants (CRTS and CSDA) program. First, that the ABF needs to raise indirect costs from donors who fund the program, and second, that the ABF needs to engage partners who are willing to fund an entire award, or to fund an award in collaboration with another partner to avoid maxing out the ABF's resources.

Jane Ransom explained how a previous CRTS in Parkinson's was jointly funded by the Parkinson's Foundation and AbbVie. The ABF has been hesitant to try to fundraise from Industry out of respect for the AAN's close relationship with Industry, and the ABF would want the AAN's blessing before pursuing any fundraising from Industry. Dr. David Dodick emphasized that the ABF does not want to interfere with the AAN's funding.

Mary Post agreed to review the status of AAN and ABF relationships with Industry fundraising with Kris Fridgen and follow up with Jane Ransom.

Dr. Merit Cudkowicz suggested that the ABF could approach Industry foundations like those at Biogen and Sanofi to avoid fundraising from the same sources within these companies as the AAN. Dr. Raymond Roos noted that AbbVie and Biogen have given large research grants recently. Dr. Jose E. Cavazos highlighted that Industry frequently partners with the NIH to fund fellowships. Dr. Phyllis C. Zee noted that societies like the Sleep Research Society may be interested in partnerships with the ABF.

2. **Crowdfunding Update:** Julia Miglets-Nelson reported that the ABF is pausing the crowdfunding program for 2020 due to COVID-19 and the need for a public awareness campaign that will create the base of support needed to make the program successful.
3. **COVID-19:** Dr. James Grotta outlined the need for research funding around the neurologic implications of COVID-19 and the ABF's progress to date. A subcommittee of the Research Strategy Task Force has met twice. The plan is to partner with the AAN, and to find a large donor or two to jump start progress. Jane Ransom added that the ABF plans to fund two types of awards, including seed grants in the \$50,000-100,000 range to established researchers, and Practice Research Training Scholarships for early career researchers engaged in health policy research to study how to get treatments for the neurologic implications of COVID-19 to communities of color and underserved communities.

Dr. David Dodick shared that a pharmaceutical company had reached out to him to get an opinion on the need for an international registry as it relates to COVID-19 and the brain and nervous system. At that time, Dr. Dodick raised the possibility of a research fund through the ABF and AAN, which seemed to interest the pharmaceutical company, however it has not gone further than this conversation because the ABF does not have the green light from the AAN to raise funds from industry.

Jane Ransom reported that the ABF staff have met with the AAN research program staff about the proposed project. Dr. Natalia Rost and Dr. Paul George have indicated that the AAN is interested in collaborating with the ABF.

Dr. Merit Cudkowicz and Dr. James Grotta proposed that the ABF consider collaborating with federal funders like the NIH. Dr. Ralph Sacco reported that the American Heart Association released an RFA for \$100,000 grants for COVID-19 research and received 750 applications for 20 awards.

Dr. Robert Griggs explained that Dr. David Dodick has established a task force around funding for COVID-19 and the brain and that the ABF staff will take these ideas back to the task force.

**Adjourned 2:59 p.m. CT.**

## Opportunities for Investing in Research

### Executive Summary

The American Brain Foundation (ABF) seeks support for its research program, which cultivates a pipeline of clinical neuroscientists, from early career researchers to established investigators. Our awards seek to advance diagnoses and treatments across disease areas and pathways, knowing that they are all connected.

### American Brain Foundation

The American Brain Foundation brings researchers and donors together to find cures for brain diseases and disorders. The ABF was established in 1992 as the philanthropic partner of the American Academy of Neurology (AAN), an international professional association of more than 36,000 neurologists and neuroscientists. To date, the ABF has provided \$30 million to more than 250 researchers. Our unique research partnership with AAN allows us to access the brightest minds to source high-reward research cutting across multiple diseases of the brain. The ABF is working to find cures for these devastating diseases by funding research, breaking down siloes between specialties and approaches, fostering communication and collaboration between researchers, and building public awareness around the prevalence of brain diseases and the urgent need for funding for research.

### Current Research Opportunities

The ABF's research program invests in research of the whole brain and all nervous system disorders, allowing us to cultivate connections in research across disease areas and pathways. Awardees for all research opportunities described below are selected by the AAN's Science Committee. Individual or corporate naming opportunities are available for most awards.

#### **1. Next Generation Research Grants**

Awards support early- and mid-career investigators researching diseases and disorders of the brain and nervous system, including stroke.

- ***Clinical Research Training Scholarship (CRTS) - \$172,500***
- ***Clinician Scientist Development Award (CSDA) - \$292,500***

Funding for early career clinical neuroscientists who are no more than 5 years post-MD and/or PhD. Awards support research specifically designed to develop treatments or enhance diagnosis of neurological disease, and may include epidemiologic or behavioral studies, clinical trials, studies of disease mechanisms, the development of new technologies, and health services and outcomes research. CRTS awards provide 2 years of funding; CSDA's provide 3 years of funding.

These awards provide critical networking and career enhancement opportunities for recipients. The AAN and ABF provide numerous networking opportunities for trainees as well as recognition at events throughout the award period. In addition, donor organizations are encouraged to invite the trainees they fund to participate in additional donor-sponsored events that highlight the donor's activities and cultivate a relationship between the donor and awardee.

- **Career Development Awards - \$575,000**

Funding for conducting basic, clinical, or translational research projects at the level of federally funded career development awards (including NIH K awards and VA CDAs) or other career development awards supported by foundations of similar scope. Funding supports three years of research by rising investigators committed to research careers.

## 2. COVID-19 & the Brain

The ABF is establishing an emergency fund to support research on the effects of COVID-19 on the brain and nervous system. Our COVID-19 & the Brain Fund will catalyze research in order to meet the urgent need to understand and treat the effects of COVID-19 on the brain, and to foster collaboration between researchers through shared data and research. Research opportunities include:

- **Seed Grants - \$115,000**

Funding for conducting basic, clinical, or translational research projects at the level of federally funded career development awards (including NIH K awards and VA CDAs) or other career development awards supported by foundations of similar scope. Funding supports three years of research by rising investigators committed to research careers.

Grants from our COVID-19 & the Brain Fund will be distributed as seed funds for established investigators, who can apply to initiate novel research projects or for matching funds for ongoing projects. At least one-third of grants will be devoted to understanding whether there is a predilection for COVID-19-related neurological sequelae in communities of color and identifying policy initiatives to assure access to treatment.

- **Practice Research Training Scholarship, Communities of Color - \$172,500**

Funding for two years of practice-based research that evaluates the translation of clinical research evidence into best clinical practice, specifically in the treatment of neurological conditions associated with COVID-19 in communities of color. Projects may include evaluation of health services, quality of care, implementation of therapies, physician performance, or patient adherence. This award aims to recognize the importance of good practice-based research or comparative effectiveness research (CER) and encourage young investigators to use studies to improve health systems and services in marginalized communities.

## 3. Early Diagnosis of Lewy Body Dementia - \$5,500,000

The ABF is seeking to accelerate progress in the diagnosis of Lewy Body Dementia (LBD) by investing in research to identify biomarker(s) of the disease to develop a definitive diagnosis. Because LBD is closely related to diseases like Alzheimer's and Parkinson's, advances in LBD research will advance research and treatments for other diseases.

The ABF has assembled a team of globally prominent LBD researchers to design a \$5.5 million research project in LBD diagnostics, which will attract top-level investigators to make progress against this devastating disease. Thus far, ABF has raised \$3.25 million for the fund.

#### **4. Named Funds**

Individuals and corporations are invited to establish named funds under the ABF umbrella which can be directed toward research on specific diseases, disease pathways, or therapies. Donors understand that research investments from their funds (which may or may not be endowed) will be directed to researchers identified by the AAN Science Committee and the ABF Research Advisory Committee.

# Early Diagnosis of Lewy Body Dementia: Research Funding Opportunity

## Executive Summary

The American Brain Foundation (ABF) is seeking to accelerate progress in the diagnosis of Lewy Body Dementia (LBD), which is the second most common form of dementia. Specifically, the Foundation is investing in research that drives toward the discovery of biomarker(s) of the disease. Patients with LBD and their caregivers endure needless suffering because of a delay in diagnosis and misdiagnoses, often leading to the prescribing of potentially harmful treatments. The lack of a disease biomarker also hinders clinical trials and the development of disease-modifying therapies and a cure.

ABF assembled a team of prominent LBD researchers and worked with them to design a \$5.5 million project which will award funds for LBD biomarker. The award levels will attract top-level investigators to make progress against this deadly disease. The American Academy of Neurology (AAN), ABF's research partner, will select the award recipient(s).

The Foundation has raised \$3.25 million toward the goal. Donations have come from organizations seeking cures for Alzheimer's Disease and Parkinson's Disease, as well as from those focused upon Lewy Body Dementia. The involvement of other disease organizations highlights the potential for a breakthrough in LBD research to advance research and knowledge in other related diseases. This approach also embodies ABF's guiding principle that when you cure one, you may cure many.

ABF seeks \$2.25 million in contributions to launch this unprecedented global research effort in LBD diagnostics. Donations earmarked to the project can be contributed to the Lewy Body Dementia Fund of the American Brain Foundation.

## Background

ABF brings researchers and donors together to find cures for the full spectrum of brain diseases and disorders. The Foundation enjoys a collaborative research relationship with our founder, the American Academy of Neurology, giving access to the best and brightest minds in Neurology and neuroscience to design and give oversight to high-reward research. The Foundation also works in partnership with 17 other national organizations focusing on specific brain diseases.

In 2018, in response to patient and caregiver requests, the American Brain Foundation (ABF) convened a committee of the world's most prominent LBD researchers around one objective: To design a research grant award that attracts the best and the brightest minds to focus on discovery of a diagnostic test for LBD. In this project, the ABF is also drawing upon its partnerships with national organizations, such as the Lewy Body Dementia Association, the Michael J. Fox Foundation, the American Academy of Neurology, who understand the urgent need for advancement in LBD diagnostics.

## Problem Statement

LBD is the most common form of dementia after Alzheimer's disease. The current lack of validated biomarkers (diagnostic test) for LBD results in delayed or misdiagnosis, exposes patients to the adverse effects and toxicity associated with

inappropriate medications, and impedes pertinent clinical and translational research, including drug discovery efforts.

The recent progress in Alzheimer's disease (AD) biomarkers that has led directly to the implementation of AD clinical trials demonstrates what is possible when biomarkers that aid diagnosis and disease progression are available.

### Purpose

**To discover an accurate method of diagnosing Lewy Body Dementia.**

### Project Design

The American Brain Foundation (ABF) and partners wish to support breakthrough research on the recognition and diagnosis of Lewy Body Dementia (LBD), specifically through the discovery of biomarker(s) of the disease. We will offer one or two five-year research grant awards from a total pool of \$5 million. Selected projects will support discovery, development, and validation of biomarkers for LBD. Projects can address disorders across the LBD spectrum and may target all disease stages, from presymptomatic to advanced disease.

AAN, the largest neurology association in the world, will supply a panel of pre-eminent scientists from its membership to select the awardees. The Michael J. Fox Foundation, the Parkinson's Foundation, the Alzheimer's Association, and the LBD Association will also appoint scientists to the selection panel.

### Project Evaluation

The selection panel discussed above will evaluate researcher(s)' progress based on a required reporting schedule.

### Project Budget

The total project budget is \$5.5 million. It includes \$5 million in money for research grants, and \$500,000 toward the core costs of marketing the grant opportunity, coordinating a competitive selection process, administering funds, and managing the evaluation process.

\* \* \* \* \*

The American Brain Foundation is seeking \$2.25 million to complete funding and launch the project which will drive discovery in LBD diagnostics. Donations earmarked to the project can be contributed to the Lewy Body Dementia Fund of the American Brain Foundation.



<b>Gift Amount</b>	<b>Naming Opportunity</b>	<b>Examples</b>
<b>\$4 million</b>	<b>Name the research grant award</b>	The John Doe Award of the American Brain Foundation in LBD Diagnostics
<b>\$1.5 million</b>	<b>Sponsored by</b>	The John Doe Award of the American Brain Foundation in LBD Diagnostics  Sponsored by The Jane Doe Foundation, etc.
<b>\$500,000</b>	<b>Supporters list</b>	The John Doe Award of the American Brain Foundation in LBD Diagnostics  Sponsored by The Jane Doe Foundation, etc.  With Support from Richard Roe, etc.
<b>Other</b>	<b>Naming Opportunity</b>	<b>Examples</b>
<b>Assign a scientist to the selection committee</b>	<b>Consulting Partner</b>	The John Doe Award of the American Brain Foundation in LBD Diagnostics  Sponsored by The Jane Doe Foundation, etc.  With Support from Richard Roe, etc.  Consulting Partners The John Roe Association, etc.
<b>Distribution of RFA, administration of selection process, grant payments, and reporting</b>	<b>Research Partner</b>	The John Doe Award of the American Brain Foundation in LBD Diagnostics  Sponsored by The Jane Doe Foundation, etc.  Research Partner The Jane Roe Society  With Support from Richard Roe, etc.  Consulting Partners The John Roe Association, etc.



## **Lewy Body Dementia Committee**

### **John C. Morris, MD, Committee Chair**

Friedman Distinguished Professor of Neurology  
Director, Knight Alzheimer Disease Research Center  
Washington University School of Medicine

### **Bradley F. Boeve, MD**

Consultant  
Department of Neurology and  
Center for Sleep Medicine  
Professor of Neurology  
College of Medicine  
Mayo Clinic

### **Jennifer Goldman, MD, MS**

Section Chief, Parkinson's Disease and Movement Disorders  
Rehabilitation at Shirley Ryan AbilityLab  
Professor of Physical Medicine and Rehabilitation and Neurology  
Northwestern University

### **John H. Growdon, MD**

Director, Memory and Movement Disorders Unit  
Massachusetts General Hospital

### **Oscar Lopez, MD**

Director, Alzheimer's Research Center  
University of Pittsburgh

### **Karen S. Marder, MD, MPH**

Chief of the Division of Aging and Dementia  
Sally Kerlin Professor of Neurology  
Columbia University Medical Center

### **Ian McKeith, MD**

Newcastle University Institute for Ageing  
Biomedical Research Building  
Campus for Ageing and Vitality

### **John Trojanowski, MD, PhD**

University of Pennsylvania  
William Maul Measey-Truman G. Schnabel, Jr., M.D.  
Professor of Geriatric Medicine and Gerontology  
Center for Neurodegenerative Disease Research  
University of Pennsylvania School of Medicine

## **COVID-19 Research Fund: Understanding the Neurological Effects of COVID-19 on Communities of Color**

**CHAIR:**

David W. Dodick, MD, FAAN

**VICE CHAIR:**

Susan Schneider Williams, BFA

**SECRETARY:**

Shafali Jeste, MD, FAAN

**TREASURER:**

James A. Essey

**IMMEDIATE PAST CHAIR:**

Kevin Goodno

**HONORARY CHAIR:**

Walter F. Mondale

**DIRECTORS:**

David Eagleman, PhD

Jimmy Erwin

Jacqueline French, MD

Dan Gasby

Robert C. Griggs, MD, FAAN

James C. Grotta, MD, FAAN

Frances Jensen, MD, FACP,  
FAAN

Sharon L. Klein

Cindy McCain

Suzanne Miller

Ronald C. Petersen, PhD, MD,  
FAAN

Sean Sansiveri

Martin Shenkman, CPA, MBA,  
PFS, AEP, JD

Joseph I. Sirven, MD, FAAN

Ben Utecht

**EX OFFICIO DIRECTORS:**

James C. Stevens, MD, FAAN

**EX OFFICIO,**

**NON-VOTING DIRECTORS:**

Jane Ransom

Mary E. Post, MBA, CAE

**HONORARY DIRECTORS:**

Rich Clifford

Richard Essey

Leeza Gibbons

Billy McLaughlin

### Executive Summary

The American Brain Foundation (ABF) is establishing an emergency fund to support research on the effects of COVID-19 on the brain and nervous system. Our COVID-19 & the Brain Fund will catalyze research in order to meet the urgent need to understand and treat the effects of COVID-19 on the brain, and it will foster collaboration between researchers through shared data and research.

Specifically, we seek funding for scientific and policy research on the neurologic effects of COVID-19 on communities of color and on policy initiatives to ensure equitable treatment.

The ABF is uniquely positioned to address this issue due to our unique partnership with the American Academy of Neurology (AAN), an international professional association of more than 36,000 neurologists and neuroscientists, which gives us immediate access to the brightest minds in the field.

### Need

Evidence of the disproportionate impact of COVID-19 on communities of color strongly suggests that these communities will also bear the brunt of the neurological problems emerging in patients with the disease. While representing only 13% of the US population, African Americans accounted for 34% of confirmed COVID-19 cases nationwide as of mid-April. Moreover, African American and Hispanic/Latino people are nearly twice as likely to die from COVID-19 than White people (Centers for Disease Control, April 20, 2020).

American Indians are also disproportionately affected by COVID-19, especially on reservations lacking in indoor plumbing. The Mississippi Band of Choctaw Indians, the Ho-Chunk Nation, the Navajo Nation, the Pueblo of San Felipe, and the Pueblo of Zia have astonishingly high reservation-based COVID-19 rates per 100,000 at 500, 800, 1100, 1400 and 3300, respectively (according to COVID-19 impact data from [Indian Country Today](#) and population estimates from the U.S. Census ACS 2018 1-Year Data).

People of color are overrepresented in “essential” work environments (such as meat packing, health care, transportation, delivery, and other service industries) where COVID-19 spreads most rapidly. Furthermore, these communities are over-represented in the lower socio-economic strata of society, making them more likely to have co-morbidities which make them more susceptible to be infected by and die from COVID-19. For example, African Americans in the United States have high levels of hypertension, diabetes, and kidney disease compared to the general population. According to the Centers for Disease Control and Prevention (CDC), Native Americans experience diabetes three times more than any other racial or ethnic group in the United States, and have the highest rates of asthma.

As a result of these higher rates of infection and acute cases of COVID-19, communities of color are also more likely to experience neurological symptoms from the virus. Even as communities of color suffer disproportionately from COVID-19, evidence is mounting of complex neurological complications related to the disease. There is an urgent need to initiate extensive research in this area, with an understanding that people of color are disproportionately affected.

Although COVID-19 has been described primarily as a disease of the lungs, there is emerging evidence that neurological symptoms and signs manifest in over one-third of patients with COVID-19. In fact, the myriad of neurological symptoms, including loss of smell, stroke, and inflammation of the brain, nerves, and nervous system suggest widespread involvement of the nervous system. In addition, there is emerging evidence that COVID-19 may also exacerbate underlying neurological diseases; and it may have long-term effects on the brain and nervous system, including cognitive dysfunction and other chronic neurological diseases.

It is currently not clear whether patients who have had mild cases of COVID-19 have been affected by neurological symptoms, nor do we yet know what types of neurological symptoms may emerge in COVID-19 patients well after they are no longer acutely sick. We know that people born during the 1918 influenza pandemic had a 2-3-fold higher risk of Parkinson’s Disease than those born prior to 1888 or after 1924. Researchers expect that, like the 1918 influenza pandemic and subsequent influenza outbreaks, we may see long-lasting neurological symptoms emerge in patients affected by COVID-19.

## Objectives

We have three objectives for advancing research on COVID-19 and the brain:

1. Understand how COVID-19 affects the brain and nervous system;
2. Understand whether there is a predilection for COVID-19-related neurological sequelae in communities of color and identify policy initiatives to ensure access to treatment;
3. Identify and track the long-term effects of COVID-19 and its treatments on the brain and nervous system.

## Program

The ABF, in coordination with our research partner, the AAN, will make grants for research to advance understanding and treatments according to our objectives. Grants from our COVID-19 & the Brain Fund will be distributed as seed funds for established investigators, who can apply to initiate novel research projects or for matching funds for ongoing projects.

The Research Advisory Committee of the ABF (see Attachment A) is collaborating with the AAN's Science Committee on a vetting process which will direct funds to world-class research by the best and brightest scientists.

Grants will be in the \$100K range, with ABF aiming to distribute at least \$1M by the end of 2020 to launch and strengthen research. In accordance with ABF's gift acceptance policies a 10 percent program management fee will be charged against all gifts to the new fund.

At least one-third of grants will be devoted to understanding whether there is a predilection for COVID-19-related neurological sequelae in communities of color and identifying policy initiatives to ensure access to treatment. In addition to medical research, we will support Practice Research Training Scholarships focused on communities of color. These will be two-year awards for practice-based research, which is defined as "clinical research that evaluates translation of evidence into best clinical practice." This may include evaluation of health services, quality of care, implementation of therapies, physician performance, or patient adherence. These scholarships will encourage young investigators to use studies to improve health systems and services for patients of color.

## American Brain Foundation

The ABF is uniquely positioned to support researchers who are beginning to study the effects of COVID-19 on the brain. Our close working relationship with the AAN, the world's largest professional association of neurologists and neuroscientists, gives us

access to the brightest minds across all areas of brain diseases and nervous system disorders and ensures that funds flow to well-vetted, world-class research. Together ABF and AAN have already supported more than 250 researchers with upwards of \$30M for investigations across the spectrum of brain diseases and disorders.

We know that brain diseases and nervous system disorders are interconnected, and that finding a cure for one will lead to a cure for many. This whole brain approach has already been crucial as researchers identify neurological symptoms, such as the loss of smell, that can provide early indications of COVID-19 infection.

### COVID-19 & the Brain Fund

Gifts to the ABF's COVID-19 & the Brain Fund will unlock the naming opportunities on the attached chart. The ABF will be happy to discuss the visibility opportunities associated with each level, or to craft another level of support based upon your potential gift.

We invite you to contribute to this project, demonstrating your commitment to finding cures and treatments for the urgent neurological symptoms of COVID-19, and to assuring equal access to health care systems and equitable treatment for all.

Gift Amount	Naming Opportunity	Example
\$1,000,000	Your company in title of fund	The [YOUR COMPANY'S NAME] COVID-19 & the Brain Fund of the American Brain Foundation
\$750,000	Champions	<p>The _____ COVID-19 &amp; the Brain Fund of the American Brain Foundation</p> <p>Champions:</p> <p><b>[YOUR COMPANY'S NAME]</b></p>
\$500,000	Partners	<p>The _____ COVID-19 &amp; the Brain Fund of the American Brain Foundation</p> <p>Champions:</p> <p>_____</p> <p>Partners:</p> <p><b>[YOUR COMPANY'S NAME]</b></p>
\$250,000	Supporters	<p>The _____ COVID-19 &amp; the Brain Fund of the American Brain Foundation</p> <p>Champions:</p> <p>_____</p> <p>Partners:</p> <p>_____</p> <p>Supporters:</p> <p><b>[YOUR COMPANY'S NAME]</b></p>